Royalty Pharma Officer Entity Files Form 144 to Sell $5.85M in Class A Shares Under 10b5-1 Plan

Executive Summary

On September 22, 2026, SCH Investment Partners LLC, associated with officer Christopher Hite at Royalty Pharma plc (NASDAQ: RPRX), filed a Form 144 notifying the SEC of its intent to sell 100,000 Class A Ordinary Shares. The aggregate market value of the proposed transaction is approximately $5,846,972.43, representing an implied share price of $58.47.

Transaction Details

• Security: Class A Ordinary Shares
• Broker: Merrill Lynch
• Proposed Sale Date: September 22, 2026
• Shares to be Sold: 100,000
• Shares Outstanding: 445,277,344 (proposed sale represents ~0.02% of total outstanding)
• Acquisition Origin: Acquired directly from the issuer in a private transaction on May 13, 2024.

10b5-1 Plan and Prior Activity

The filing indicates that this planned disposition is being executed in connection with a pre-arranged Rule 10b5-1 trading plan adopted on March 20, 2026.

Over the preceding three months, SCH Investment Partners LLC has executed several scheduled sales under the plan:

• June 23, 2026: 150,000 shares for gross proceeds of $8,166,766.13
• June 30, 2026: 100,000 shares for gross proceeds of $5,645,700.97
• August 18, 2026: 100,000 shares for gross proceeds of $5,991,122.91

Combined with the current filing, sales over the last 90+ days total 450,000 shares worth approximately $25.65 million.

Market Impact & Significance

The trading significance is assessed as Medium. While the transaction value exceeds $5.8 million and forms part of an ongoing multi-million dollar liquidation program, it is executed under a pre-established 10b5-1 plan and represents a negligible fraction (0.02%) of Royalty Pharma's 445.3 million shares outstanding.